Sight Sciences vs TELA Bio
TELA Bio reported revenue of $80 million in fiscal 2025, about the same as Sight Sciences' $77 million in fiscal 2025. Sight Sciences' revenue fell 3.1% in its latest year, and TELA Bio's grew 15.8%. Sight Sciences had an operating margin of -48.0%, against -42.0% at TELA Bio. Free cash flow was −$30 million at Sight Sciences and −$29 million at TELA Bio.
Side by side
| Sight Sciences | TELA Bio | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $77M | $80M |
| Revenue growth | −3.1% | 15.8% |
| Revenue growth a year, last 5 years | 22.9% | 34.6% |
| Gross margin | 86.2% | 67.7% |
| Operating margin | −48.0% | −42.0% |
| Net margin | −49.7% | −48.4% |
| Free cash flow | −$30M | −$29M |
| Free cash flow margin | −38.7% | −35.7% |
| Return on capital | — | −190.2% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 4.0% | 64.6% |
| Last close | $10.62 | $0.73 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $184,799, sold $2.3 million | bought $186,250, sold $0 |
| Piotroski F-score | 5 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Sight SciencesTELA Bio
Operating margin
Percent of revenue
Sight SciencesTELA Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Sight SciencesTELA Bio
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Sight Sciences and TELA Bio pages.